Shanghai Hengrui Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 2001-12-04
- Employees
- -
- Market Cap
- -
- Website
- http://www.shhrp.com
Phase Ⅱ Study of Adductor Canal Block With HR18034 for Postsurgical Pain Management
Phase 2
Active, not recruiting
- Conditions
- Total Knee Arthroplasty
- Interventions
- Drug: HR18034;Ropivacaine Hydrochloride Injection
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 89
- Registration Number
- NCT05561309
- Locations
- 🇨🇳
Dongguan People's Hospital, Dongguan, Guangdong, China
Efficacy and Safety Study of SHR-1819 Injection in Adult Patients With Severe Atopic Dermatitis
Phase 2
Completed
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: PlaceboDrug: SHR1819
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 158
- Registration Number
- NCT05549947
- Locations
- 🇨🇳
Huashan Sub-Hospital of Fudan University, Shanghai, Shanghai, China
A Study of HR19024 in Subjects With Advanced Solid Tumor
Phase 1
- Conditions
- Advanced Solid Tumor
- Interventions
- Drug: HR19024
- First Posted Date
- 2022-07-19
- Last Posted Date
- 2022-09-01
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05463432
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of SHR-1501 Alone or in Combination With BCG in Subjects With NMIBC
Phase 1
Recruiting
- Conditions
- High-risk NMIBC
- Interventions
- Drug: SHR-1501
- First Posted Date
- 2022-06-08
- Last Posted Date
- 2024-08-01
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT05410730
- Locations
- 🇨🇳
Peking University First Hospital, Beijing, Beijing, China
A Trial of HR18034 for Postoperative Analgesia in Subjects Undergoing Hemorrhoidectomy.
Phase 2
Completed
- Conditions
- Postsurgical Pain Management
- Interventions
- Drug: ropivacaine HCl.Drug: HR18034
- First Posted Date
- 2022-05-17
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 86
- Registration Number
- NCT05376904
- Locations
- 🇨🇳
Li Huili Hospital of Ningbo Medical Center, Ningbo, Zhejiang, China
🇨🇳Central Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China
🇨🇳The Second Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
A Trial of SHR6508 in Secondary Hyperparathyroidism
Phase 1
Completed
- Conditions
- Secondary Hyperparathyroidism
- Interventions
- Drug: SHR6508；Placebo
- First Posted Date
- 2022-02-02
- Last Posted Date
- 2023-08-08
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 54
- Registration Number
- NCT05221008
- Locations
- 🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, Guangdong, China
Clinical Study on the Efficacy and Safety of Multiple Oral Administrations of SHR2285 Tablets in Patients Undergoing Elective Total Knee Arthroplasty
Phase 2
- Conditions
- Prevention of Venous Thrombosis After TKA
- Interventions
- Drug: SHR2285 tabletDrug: Enoxaparin
- First Posted Date
- 2022-01-24
- Last Posted Date
- 2022-03-21
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 500
- Registration Number
- NCT05203705
- Locations
- 🇨🇳
Perking Union Medical College Hospital, Beijing, Beijing, China
A STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE SUBCUTANEOUS INJECTIONS OF SHR-1819 IN PATIENTS WITH MODERATE TO SEVERE ATOPIC DERMATITIS
Phase 1
- Conditions
- Moderate to Severe Atopic Dermatitis
- Interventions
- Drug: SHR-1819 injection or placebo
- First Posted Date
- 2022-01-19
- Last Posted Date
- 2022-01-19
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT05197023
A Study of SHR-A1909 in Subjects With Advanced Malignant Tumors
Phase 1
- Conditions
- Advanced Malignant Cancer
- Interventions
- Drug: SHR-1909 injection
- First Posted Date
- 2021-12-17
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT05162469
- Locations
- 🇨🇳
Jilin Cancer Hospital, Changchun, Jilin, China
A First-in-human Study of HRS2398 Tablets in Subjects With Advanced Malignant Tumors
Phase 1
Completed
- Conditions
- Advanced Malignant Tumor
- Interventions
- Drug: HRS2398 Tablets
- First Posted Date
- 2021-12-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Target Recruit Count
- 28
- Registration Number
- NCT05144061
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Zhengzhou University/Henan Cancer Hospital, Zhengzhou, Henan, China
© Copyright 2025. All Rights Reserved by MedPath